[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content
Springer Nature Link
Log in

Circumventing Tumor Resistance to Chemotherapy by Nanotechnology

  • Protocol
  • First Online:
Multi-Drug Resistance in Cancer

Part of the book series: Methods in Molecular Biology ((MIMB,volume 596))

Abstract

Patient relapse and metastasis of malignant cells is very common after standard cancer treatment with surgery, radiation, and/or chemotherapy. Chemotherapy, a cornerstone in the development of present day cancer therapy, is one of the most effective and potent strategies to treat malignant tumors. However, the resistance of cancer cells to the drugs remains a significant impediment to successful chemotherapy. An additional obstacle is the inability of chemotherapeutic drugs to selectively target tumor cells. Almost all the anticancer agents have severe side effects on normal tissues and organs. The toxicity of currently available anticancer drugs and the inefficiency of chemotherapeutic treatments, especially for advanced stages of the disease, have limited the optimization of clinical drug combinations and effective chemotherapeutic protocols. Nanomedicine allows the release of drugs by biodegradation and self-regulation of nanomaterials in vitro and in vivo. Nanotechnologies are characterized by effective drug encapsulation, controllable self-assembly, specificity and biocompatibility as a result of their own material properties. Nanotechnology has the potential to overcome current chemotherapeutic barriers in cancer treatment, because of the unique nanoscale size and distinctive bioeffects of nanomaterials. Nanotechnology may help to solve the problems associated with traditional chemotherapy and multidrug resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
£29.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Protocol
GBP 34.95
Price includes VAT (United Kingdom)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
GBP 71.50
Price includes VAT (United Kingdom)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
GBP 129.99
Price includes VAT (United Kingdom)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
GBP 89.99
Price includes VAT (United Kingdom)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Leaf C (2004) Why we’re losing the war on cancer (and how to win it). Fortune 149:76–82

    Google Scholar 

  2. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615–627

    Article  CAS  PubMed  Google Scholar 

  3. Calatozzolo C, Gelati M, Ciusani E et al (2005) Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 74:113–121

    Article  CAS  PubMed  Google Scholar 

  4. Links M, Brown R (1999) Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev Mol Med 1999:1–21

    CAS  PubMed  Google Scholar 

  5. McNeil SE (2005) Nanotechnology for the biologist. J Leukoc Biol 78:585–594

    Article  CAS  PubMed  Google Scholar 

  6. Grodzinski P, Silver M, Molnar LK (2006) Nanotechnology for cancer diagnostics: promises and challenges. Expert Rev Mol Diagn 6:307–318

    Article  CAS  PubMed  Google Scholar 

  7. Stella B, Arpicco S, Peracchia MT et al (2000) Design of folic acid-conjugated nanoparticles for drug targeting. J Pharm Sci 89:1452–1464

    Article  CAS  PubMed  Google Scholar 

  8. Kontermann RE (2006) Immunoliposomes for cancer therapy. Curr Opin Mol Ther 8:39–45

    CAS  PubMed  Google Scholar 

  9. van Vlerken LE, Duan ZF, Seiden MV, Amiji MM (2007) Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res 67:4843–4850

    Article  PubMed  Google Scholar 

  10. Kubiak C, Couvreur P, Manil L, Clausse B (1989) Increased cytotoxicity of nanoparticle-carried Adriamycin in vitro and potentiation by verapamil and amiodarone. Biomaterials 10:553–556

    Article  CAS  PubMed  Google Scholar 

  11. Colin de Verdiere A, Dubernet C, Nemati F et al (1994) Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chemother Pharmacol 33:504–508

    CAS  PubMed  Google Scholar 

  12. Soma CE, Dubernet C, Bentolila D, Benita S, Couvreur P (2000) Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 21:1–7

    Article  CAS  PubMed  Google Scholar 

  13. Shoji Y, Nakashima H (2004) Current status of delivery systems to improve target efficacy of oligonucleotides. Curr Pharm Des 10:785–796

    Article  CAS  PubMed  Google Scholar 

  14. Brigui I, Djavanbakht-Samani T, Jolles B, Pigaglio S, Laigle A (2003) Minimally modified phosphodiester antisense oligodeoxyribonucleotide directed against the multidrug resistance gene mdr1. Biochem Pharmacol 65:747–754

    Article  CAS  PubMed  Google Scholar 

  15. Reddy LH, Sharma RK, Murthy RS (2004) Enhanced tumour uptake of doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles in mice bearing Dalton’s lymphoma tumour. J Drug Target 12:443–451

    Article  CAS  PubMed  Google Scholar 

  16. Gref R, Minamitake Y, Peracchia MT et al (1994) Biodegradable long-circulating polymeric nanospheres. Science 263:1600–1603

    Article  CAS  PubMed  Google Scholar 

  17. Stolnik S, Dunn SE, Garnett MC et al (1994) Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm Res 11:1800–1808

    Article  CAS  PubMed  Google Scholar 

  18. Peracchia MT, Fattal E, Desmaele D et al (1999) Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release 60:121–128

    Article  CAS  PubMed  Google Scholar 

  19. Calvo P, Gouritin B, Chacun H et al (2001) Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 18:1157–1166

    Article  CAS  PubMed  Google Scholar 

  20. Calvo P, Gouritin B, Villarroya H et al (2002) Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J NeuroSci 15:1317–1326

    Article  PubMed  Google Scholar 

  21. Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54:631–651

    Article  CAS  PubMed  Google Scholar 

  22. Brigger I, Morizet J, Aubert G et al (2002) Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J Pharmacol Exp Ther 303:928–936

    Article  CAS  PubMed  Google Scholar 

  23. Maeda H, Greish K, Fang J (2006) The EPR effect and polymeric drugs: a paradigm shift for cancer chemotherapy in the 21st century. In: Satchi-Fainaro R, Duncan R (eds) Polymer therapeutics II: polymers as drugs, conjugates and gene delivery systems. Springer-Verlag, Berlin, Heidelberg, pp 103–121

    Google Scholar 

  24. Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189–207

    Article  CAS  PubMed  Google Scholar 

  25. Yuan F, Dellian M, Fukumura D et al (1995) Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55:3752–3756

    CAS  PubMed  Google Scholar 

  26. Kopecek J, Kopeckova P, Minko T, Lu ZR, Peterson CM (2001) Water soluble polymers in tumor targeted delivery. J Control Release 74:147–158

    Article  CAS  PubMed  Google Scholar 

  27. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK (2000) Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 60:4324–4327

    CAS  PubMed  Google Scholar 

  28. Jain RK (1994) Barriers to drug delivery in solid tumors. Sci Am 271:58–65

    Article  CAS  PubMed  Google Scholar 

  29. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S (2004) Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 56:1177–1192

    Article  CAS  PubMed  Google Scholar 

  30. Krishna R, Mayer LD (2000) Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11:265–283

    Article  CAS  PubMed  Google Scholar 

  31. Koo OM, Rubinstein I, Onyuksel H (2006) Camptothecin in sterically stabilized phospholipid nano-micelles: a novel solvent pH change solubilization method. J Nanosci Nanotechnol 6:2996–3000

    Article  CAS  PubMed  Google Scholar 

  32. Yih TC, Al-Fandi M (2006) Engineered nanoparticles as precise drug delivery systems. J Cell Biochem 97:1184–1190

    Article  CAS  PubMed  Google Scholar 

  33. Madshus IH (1988) Regulation of intracellular pH in eukaryotic cells. Biochem J 250:1–8

    CAS  PubMed  Google Scholar 

  34. Mahoney BP, Raghunand N, Baggett B, Gillies RJ (2003) Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 66:1207–1218

    Article  CAS  PubMed  Google Scholar 

  35. Acker T, Plate KH (2004) Hypoxia and hypoxia inducible factors (HIF) as important regulators of tumor physiology. Cancer Treat Res 117:219–248

    CAS  PubMed  Google Scholar 

  36. Hussein D, Estlin EJ, Dive C, Makin GW (2006) Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther 5:2241–2250

    Article  CAS  PubMed  Google Scholar 

  37. Krishnamurthy P, Schuetz JD (2006) Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 46:381–410

    Article  CAS  PubMed  Google Scholar 

  38. Ahmad KA, Iskandar KB, Hirpara JL, Clement MV, Pervaiz S (2004) Hydrogen peroxide-mediated cytosolic acidification is a signal for mitochondrial translocation of Bax during drug-induced apoptosis of tumor cells. Cancer Res 64:7867–7878

    Article  CAS  PubMed  Google Scholar 

  39. Savic R, Luo L, Eisenberg A, Maysinger D (2003) Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 300:615–618

    Article  CAS  PubMed  Google Scholar 

  40. Geng Y, Dalhaimer P, Cai S et al (2007) Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2:249–255

    Article  CAS  PubMed  Google Scholar 

  41. Chen C, Xing G, Wang J et al (2005) Multihydroxylated [Gd@C82(OH)22]n nanoparticles: antineoplastic activity of high efficiency and low toxicity. Nano Lett 5:2050–2057

    Article  CAS  PubMed  Google Scholar 

  42. Lu J, Liong M, Zink JI, Tamanoi F (2007) Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 3:1341–1346

    Article  CAS  PubMed  Google Scholar 

  43. Wartlick H, Spankuch-Schmitt B, Strebhardt K, Kreuter J, Langer K (2004) Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles. J Control Release 96:483–495

    Article  CAS  PubMed  Google Scholar 

  44. Rosenberg B, Vancamp L, Krigas T (1965) Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205:698–699

    Article  CAS  PubMed  Google Scholar 

  45. Rosenberg B (1977) Noble metal complexes in cancer chemotherapy. Adv Exp Med Biol 91:129–150

    CAS  PubMed  Google Scholar 

  46. Hill JM, Speer RJ (1982) Organo-platinum complexes as antitumor agents (review). Anticancer Res 2:173–186

    CAS  PubMed  Google Scholar 

  47. Rosenberg B, VanCamp L, Trosko JE, Mansour VH (1969) Platinum compounds: a new class of potent antitumour agents. Nature 222:385–386

    Article  CAS  PubMed  Google Scholar 

  48. Oliver T, Mead G (1993) Testicular cancer. Curr Opin Oncol 5:559–567

    Article  CAS  PubMed  Google Scholar 

  49. Liang XJ, Shen DW, Gottesman MM (2004) A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells. J Inorg Biochem 98:1599–1606

    Article  CAS  PubMed  Google Scholar 

  50. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573–584

    Article  CAS  PubMed  Google Scholar 

  51. Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99:14298–14302

    Article  CAS  PubMed  Google Scholar 

  52. Katano K, Kondo A, Safaei R et al (2002) Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62:6559–6565

    CAS  PubMed  Google Scholar 

  53. Holzer AK, Howell SB (2006) The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 66:10944–10952

    Article  CAS  PubMed  Google Scholar 

  54. Ishikawa T (1992) The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci 17:463–468

    Article  CAS  PubMed  Google Scholar 

  55. Kelland LR, Mistry P, Abel G et al (1992) Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res 52:3857–3864

    CAS  PubMed  Google Scholar 

  56. Shen DW, Goldenberg S, Pastan I, Gottesman MM (2000) Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol 183:108–116

    Article  CAS  PubMed  Google Scholar 

  57. Lin X, Okuda T, Holzer A, Howell SB (2002) The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 62:1154–1159

    Article  CAS  PubMed  Google Scholar 

  58. Burger KN, Staffhorst RW, de Vijlder HC et al (2002) Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat Med 8:81–84

    Article  CAS  PubMed  Google Scholar 

  59. Nishiyama N, Okazaki S, Cabral H et al (2003) Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 63:8977–8983

    CAS  PubMed  Google Scholar 

  60. Gordon AN, Tonda M, Sun S, Rackoff W (2004) Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95:1–8

    Article  CAS  PubMed  Google Scholar 

  61. Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803

    Article  CAS  PubMed  Google Scholar 

  62. Gore ME, Atkinson RJ, Thomas H et al (2002) A phase II trial of ZD0473 in platinum-pretreated ovarian cancer. Eur J Cancer 38:2416–2420

    Article  CAS  PubMed  Google Scholar 

  63. Iinuma H, Maruyama K, Okinaga K et al (2002) Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 99:130–137

    Article  CAS  PubMed  Google Scholar 

  64. Briz O, Serrano MA, Rebollo N et al (2002) Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. Mol Pharmacol 61:853–860

    Article  CAS  PubMed  Google Scholar 

  65. Li S, Khokhar AR, Perez-Soler R, Huang L (1995) Improved antitumor activity of cis-Bis-neodecanoato-trans-R, R-1, 2- diaminocyclohexaneplatinum (II) entrapped in long-circulating liposomes. Oncol Res 7:611–617

    CAS  PubMed  Google Scholar 

  66. Mori A, Wu SP, Han I et al (1996) In vivo antitumor activity of cis-bis-neodecanoato-trans-R, R-1, 2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes. Cancer Chemother Pharmacol 37:435–444

    Article  CAS  PubMed  Google Scholar 

  67. Barroug A, Glimcher MJ (2002) Hydroxyapatite crystals as a local delivery system for cisplatin: adsorption and release of cisplatin in vitro. J Orthop Res 20:274–280

    Article  CAS  PubMed  Google Scholar 

  68. Emerich DF, Snodgrass P, Lafreniere D et al (2002) Sustained release chemotherapeutic microspheres provide superior efficacy over systemic therapy and local bolus infusions. Pharm Res 19:1052–1060

    Article  CAS  PubMed  Google Scholar 

  69. Avgoustakis K, Beletsi A, Panagi Z et al (2002) PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release 79: 123–135

    Article  CAS  PubMed  Google Scholar 

  70. Kovacs AF, Turowski B (2002) Chemoembolization of oral and oropharyngeal cancer using a high-dose cisplatin crystal suspension and degradable starch microspheres. Oral Oncol 38:87–95

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Mr. Xu Zhang for research assistance during the preparation of its manuscript. We also appreciate the help of Dr. Michael M. Gottesman for critical reading of the manuscript. Our work is financially supported by the Chinese Academy of Sciences “Hundred Talents Program” (07165111ZX), and the National Basic Research Program of China (2009CB930200). This work was also supported in part by NIH/ NCRR/ RCMI 2G12RR003048, NIH 5U 54CA091431, and USAMRMC W81XWH-05-1-0291 grants.

Author information

Authors and Affiliations

  1. Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanosciences and Technology of China, Beijing, China

    Xing-Jie Liang, Chunying Chen & Yuliang Zhao

  2. Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China

    Yuliang Zhao

Authors
  1. Xing-Jie Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chunying Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuliang Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul C. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xing-Jie Liang .

Editor information

Editors and Affiliations

  1. College of Life Sciences, Nankai University, Weijin Rd. 94, Tianjin, 300071, China, People's Republic

    Jun Zhou

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Humana Press, a part of Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Liang, XJ., Chen, C., Zhao, Y., Wang, P.C. (2010). Circumventing Tumor Resistance to Chemotherapy by Nanotechnology. In: Zhou, J. (eds) Multi-Drug Resistance in Cancer. Methods in Molecular Biology, vol 596. Humana Press. https://doi.org/10.1007/978-1-60761-416-6_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-416-6_21

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-415-9

  • Online ISBN: 978-1-60761-416-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation